Welcome to the 15th International Child Neurology Congress

On behalf of the International Child Neurology Association, it is my great pleasure to welcome you to the 15 th International Child Neurology Congress being held in Mumbai, India in Nov. 2018. Our congress theme is 'Protecting the developing brain'. We aim to provide an overview of Childhood Neurological Disorders from a Global Perspective with strong representation from all six major geographic regions. The scientific program will feature internationally recognized experts who will provide the latest advances within different subspecialties of child neurology, including two tribute lectures to honour the lifetime contributions of two remarkable pioneers of Child Neurology, Dr. Yukio Fukuyama and Dr. Masaya Segawa. This will be combined with a strong educational program through breakfast teaching courses, workshops, afternoon tea symposia with algorithmic approaches and instructive case presentations and evening master classes.

Several exciting ICNA initiatives will also be featured. There will be a symposium dedicated to a review of the integral components of solid clinical research methodology and rigorous study design including the needed framework for prospective randomized, double-blind, placebo-controlled trials. The ICNC2018 

Continue reading

Cures Within Reach announces Industry Patient Impact Clinical Award for Prof Lieven Lagae

Prof Lieven Lagae, ICNA Executive Board Member &  Director of the Childhood Epilepsy Program at the KUL University Hospitals is the recipient of "Cures within Research" 5th Annual Global Health Repurposing Awards. Prof Lagae has been awarded the new Industry Patient Impact Clinical Award.

Award recipients will be recognized at the Global Health Repurposing Awards on June 27, 2017 at the 6th Annual Global Health Drug Repositioning and Repurposing Conference in Chicago, IL.

We are very proud to acknowledge the achievements of our fellow ICNA Executive Board member, Dr. Lieven Lagae of KUL University Hospitals in Belgium, for his "Cures Within Reach Industry Patient Impact Clinical Award 2017" which has been given in recognition of his pioneering research and world-wide efforts to repurpose the drug fenfluramine for Dravet syndrome patients.


Continue reading

New drug targeting histamine for cataplexy in narcolepsy

A randomized, double-blinded trial has shown that pitolisant, a drug that targets a specific histamine receptor, can reduce cataplexy, a very disabling symptom of narcolepsy. Cataplexy is a sudden and uncontrollable muscle weakness or paralysis that comes on during the day and is often triggered by a strong emotion, such as excitement or laughter. The loss of muscle tone in cataplexy occurs because of the inability to regulate sleep and awake states -- meaning that elements o...
Continue reading

Nodding syndrome caused by response to parasitic protein


​ Researchers have linked Nodding syndrome, a devastating form of pediatric epilepsy found in specific areas of east Africa, to a parasitic worm that can cause river blindness. The study, published in Science Translational Medicine, suggests that the mysterious neurological disease may be caused by an autoimmune response to the parasitic proteins. "This study identifies a cause of Nodding syndrome. But more broadly, these findings provide a novel perspective on epilepsy and suggest that som...
Continue reading

Role for GABA in accelerating brain activity - new mechanism for epilepsy

Following a prolonged epileptic seizures  neural connections of the brain may be rewired in an incorrect way. This may result in seizures that are difficult to control with medication. Mechanisms underlying this phenomenon are not entirely known, which makes current therapies ineffective in some patients. In a study, published in the Annals of Neurology, researchers at the  Neuroscience Center of the University of Helsinki have shown a role for gamma-aminobutyric acid (GABA),...
Continue reading

pleasedonate